Search results
Results From The WOW.Com Content Network
Moderna, Inc. (/ m ə ˈ d ɜːr n ə / mə-DUR-nə) [4] is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
In 2015, Moderna secured a record-breaking $450 million in startup funding, in addition to $340 million in upfront payments from other biopharmaceutical companies AstraZeneca ($240 million) and ...
Derrick Rossi urges Canada to place bets on biomedicine. For premium support please call: 800-290-4726 more ways to reach us
The Fortune 500 is a much-lauded list of the America's biggest companies. Qualification is solely based on a company's revenues. The 2022 edition is the 68th in its history. Holiday Spending: Get...
In 2020, Moderna partnered with Takeda Pharmaceutical Company, and the Japan Ministry of Health, Labour and Welfare (MHLW). [168] [169] The vaccine is known as "COVID-19 Vaccine Moderna Intramuscular Injection". [170] [3] In May 2021, COVID‑19 Vaccine Moderna Intramuscular Injection (formerly TAK-919) was authorized for emergency use in Japan ...
Biotech company Moderna Inc said on Wednesday it expected to raise up to $521.7 million in its initial public offering, valuing the company at about $7.8 billion at the top end of the pricing range.